Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVENTAMI-FX
2025-524664-38-00Phase 2Authorised
- Sponsor
- Azienda USL Toscana Sud Est
- Start
- Oct 2026
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fondaparinux in myocardial infarction (MI) and Left ventricular thrombosis (LVT) (2 arms), sponsored by Azienda USL Toscana Sud Est. Planned start Oct 2026; status: authorised.
02
Drugs
fondaparinux
03
Conditions
myocardial infarction (MI)Left ventricular thrombosis (LVT)
Beyond the preview
Go deeper on 2025-524664-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524664-38-00.